{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:58:12Z","timestamp":1792166292499,"version":"4.4.0"},"reference-count":157,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:00:00Z","timestamp":1736121600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270228"],"award-info":[{"award-number":["82270228"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82350105"],"award-info":[{"award-number":["82350105"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82070184"],"award-info":[{"award-number":["82070184"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["2023ZD0501200"],"award-info":[{"award-number":["2023ZD0501200"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Beijing Natural Science Foundation","doi-asserted-by":"publisher","award":["Z240019"],"award-info":[{"award-number":["Z240019"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013076","name":"National Major Science and Technology Projects of China","doi-asserted-by":"publisher","award":["2023ZD0501200"],"award-info":[{"award-number":["2023ZD0501200"]}],"id":[{"id":"10.13039\/501100013076","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005090","name":"Beijing Nova Program","doi-asserted-by":"publisher","award":["20220484235"],"award-info":[{"award-number":["20220484235"]}],"id":[{"id":"10.13039\/501100005090","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Science Bulletin"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.scib.2025.01.002","type":"journal-article","created":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T01:36:45Z","timestamp":1736041005000},"page":"765-777","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["CAR-NK cell therapy: a potential antiviral platform"],"prefix":"10.1016","volume":"70","author":[{"given":"Ming-Hao","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Juan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Jun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang-Yu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.scib.2025.01.002_b0005","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0140-6736(23)00860-7","article-title":"The unfinished agenda of communicable diseases among children and adolescents before the COVID-19 pandemic, 1990-2019: a systematic analysis of the Global Burden of Disease Study 2019","volume":"402","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.scib.2025.01.002_b0010","doi-asserted-by":"crossref","first-page":"e345","DOI":"10.1016\/S1473-3099(24)00211-1","article-title":"Plasma-based antigen persistence in the post-acute phase of COVID-19","volume":"24","author":"Peluso","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.scib.2025.01.002_b0015","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/s41586-022-05538-8","article-title":"Phenotypic signatures of immune selection in HIV-1 reservoir cells","volume":"614","author":"Sun","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.scib.2025.01.002_b0020","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1136\/gutjnl-2015-309809","article-title":"HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B","volume":"64","author":"Nassal","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.scib.2025.01.002_b0025","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00430-019-00592-y","article-title":"Cellular reservoirs of latent cytomegaloviruses","volume":"208","author":"Reddehase","year":"2019","journal-title":"Med Microbiol Immunol"},{"key":"10.1016\/j.scib.2025.01.002_b0030","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1038\/s41590-023-01601-2","article-title":"SARS-CoV-2 reservoir in post-acute sequelae of COVID-19 (PASC)","volume":"24","author":"Proal","year":"2023","journal-title":"Nat Immunol"},{"key":"10.1016\/j.scib.2025.01.002_b0035","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/s41579-019-0249-7","article-title":"Latency and lytic replication in Epstein-Barr virus-associated oncogenesis","volume":"17","author":"Munz","year":"2019","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.scib.2025.01.002_b0040","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1182\/blood.V76.12.2421.2421","article-title":"Biology and clinical relevance of human natural killer cells","volume":"76","author":"Robertson","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.scib.2025.01.002_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2021.108727","article-title":"Natural killer cells play an important role in virus infection control: antiviral mechanism, subset expansion and clinical application","volume":"227","author":"Zuo","year":"2021","journal-title":"Clin Immunol"},{"key":"10.1016\/j.scib.2025.01.002_b0050","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jaci.2022.09.022","article-title":"Human natural killer cells: form, function, and development","volume":"151","author":"Mace","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.scib.2025.01.002_b0055","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41423-019-0206-4","article-title":"Human NK cells: surface receptors, inhibitory checkpoints, and translational applications","volume":"16","author":"Sivori","year":"2019","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.scib.2025.01.002_b0060","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.smim.2006.04.002","article-title":"The balancing act: inhibitory Ly49 regulate NKG2D-mediated NK cell functions","volume":"18","author":"Malarkannan","year":"2006","journal-title":"Semin Immunol"},{"key":"10.1016\/j.scib.2025.01.002_b0065","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/319675a0","article-title":"Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy","volume":"319","author":"Karre","year":"1986","journal-title":"Nature"},{"key":"10.1016\/j.scib.2025.01.002_b0070","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/nri1863","article-title":"Self-tolerance of natural killer cells","volume":"6","author":"Raulet","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.scib.2025.01.002_b0075","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1016\/S0140-6736(00)03231-1","article-title":"Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population","volume":"356","author":"Imai","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.scib.2025.01.002_b0080","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/ni1582","article-title":"Functions of natural killer cells","volume":"9","author":"Vivier","year":"2008","journal-title":"Nat Immunol"},{"key":"10.1016\/j.scib.2025.01.002_b0085","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aat8116","article-title":"Human natural killer cells mediate adaptive immunity to viral antigens","volume":"4","author":"Nikzad","year":"2019","journal-title":"Sci Immunol"},{"key":"10.1016\/j.scib.2025.01.002_b0090","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.immuni.2015.02.008","article-title":"Cytomegalovirus infection drives adaptive epigenetic diversification of NK cells with altered signaling and effector function","volume":"42","author":"Schlums","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/j.scib.2025.01.002_b0095","first-page":"357","article-title":"HBV vaccination and HBV infection induces HBV-specific natural killer cell memory","volume":"70","author":"Wijaya","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.scib.2025.01.002_b0100","doi-asserted-by":"crossref","DOI":"10.1172\/JCI148542","article-title":"Cytomegalovirus mediates expansion of IL-15-responsive innate-memory cells with SIV killing function","volume":"131","author":"Mendez-Lagares","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1016\/j.scib.2025.01.002_b0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009132","article-title":"Memory like NK cells display stem cell like properties after Zika virus infection","volume":"16","author":"Kujur","year":"2020","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.scib.2025.01.002_b0110","doi-asserted-by":"crossref","first-page":"687","DOI":"10.3389\/fimmu.2019.00687","article-title":"Human cytomegalovirus antigen presentation by HLA-DR+NKG2C+ adaptive NK cells specifically activates polyfunctional effector memory CD4+T lymphocytes","volume":"10","author":"Costa-Garc\u00eda","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.scib.2025.01.002_b0115","doi-asserted-by":"crossref","first-page":"4688","DOI":"10.4049\/jimmunol.1402448","article-title":"An NK cell population lacking FcR\u03b3 is expanded in chronically infected HIV patients","volume":"194","author":"Zhou","year":"2015","journal-title":"J Immunol"},{"key":"10.1016\/j.scib.2025.01.002_b0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0121258","article-title":"Influenza vaccine induces intracellular immune memory of human NK cells","volume":"10","author":"Dou","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.scib.2025.01.002_b0125","doi-asserted-by":"crossref","first-page":"474","DOI":"10.3389\/fimmu.2018.00474","article-title":"Adaptive reconfiguration of natural killer cells in HIV-1 infection","volume":"9","author":"Peppa","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.scib.2025.01.002_b0130","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.149120","article-title":"Donor NKG2C homozygosity contributes to CMV clearance after haploidentical transplantation","volume":"7","author":"Yu","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.scib.2025.01.002_b0135","doi-asserted-by":"crossref","first-page":"4751","DOI":"10.1182\/blood-2012-04-419283","article-title":"Cytokine activation induces human memory-like NK cells","volume":"120","author":"Romee","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.scib.2025.01.002_b0140","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1126\/science.287.5455.1031","article-title":"Surface expression of HLA-E, an inhibitor of natural killer cells, enhanced by human cytomegalovirus gpUL40","volume":"287","author":"Tomasec","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.scib.2025.01.002_b0145","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.chom.2020.04.009","article-title":"Complex immune dysregulation in COVID-19 patients with severe respiratory failure","volume":"27","author":"Giamarellos-Bourboulis","year":"2020","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.scib.2025.01.002_b0150","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41423-020-0402-2","article-title":"Functional exhaustion of antiviral lymphocytes in COVID-19 patients","volume":"17","author":"Zheng","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.scib.2025.01.002_b0155","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.74489","article-title":"SARS-CoV-2 host-shutoff impacts innate NK cell functions, but antibody-dependent NK activity is strongly activated through non-spike antibodies","volume":"11","author":"Fielding","year":"2022","journal-title":"Elife"},{"key":"10.1016\/j.scib.2025.01.002_b0160","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.coi.2015.11.003","article-title":"SLAM family receptors in normal immunity and immune pathologies","volume":"38","author":"Wu","year":"2016","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.scib.2025.01.002_b0165","doi-asserted-by":"crossref","first-page":"e00617","DOI":"10.1128\/JVI.00617-19","article-title":"Cytomegalovirus evades TRAIL-mediated innate lymphoid cell 1 defenses","volume":"93","author":"Picarda","year":"2019","journal-title":"J Virol"},{"key":"10.1016\/j.scib.2025.01.002_b0170","doi-asserted-by":"crossref","first-page":"e02077","DOI":"10.1128\/JVI.02077-18","article-title":"Identification and functional characterization of a novel Fc gamma-binding glycoprotein in rhesus cytomegalovirus","volume":"93","author":"Kolb","year":"2019","journal-title":"J Virol"},{"key":"10.1016\/j.scib.2025.01.002_b0175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007658","article-title":"Subversion of natural killer cell responses by a cytomegalovirus-encoded soluble CD48 decoy receptor","volume":"15","author":"Martinez-Vicente","year":"2019","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.scib.2025.01.002_b0180","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/s41586-021-04142-6","article-title":"Untimely TGF\u03b2 responses in COVID-19 limit antiviral functions of NK cells","volume":"600","author":"Witkowski","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.scib.2025.01.002_b0185","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s12879-018-2991-2","article-title":"IL-10+ NK and TGF-\u03b2+ NK cells play negative regulatory roles in HIV infection","volume":"18","author":"Jiang","year":"2018","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.scib.2025.01.002_b0190","doi-asserted-by":"crossref","first-page":"e00235","DOI":"10.1128\/JVI.00235-18","article-title":"Interleukin-15-stimulated natural killer cells clear HIV-1-infected cells following latency reversal ex vivo","volume":"92","author":"Garrido","year":"2018","journal-title":"J Virol"},{"key":"10.1016\/j.scib.2025.01.002_b0195","doi-asserted-by":"crossref","first-page":"9130","DOI":"10.1038\/s41598-017-07966-3","article-title":"One-domain CD4 fused to human anti-CD16 antibody domain mediates effective killing of HIV-1-infected cells","volume":"7","author":"Li","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.scib.2025.01.002_b0200","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1053\/j.gastro.2012.10.039","article-title":"Blocking the natural killer cell inhibitory receptor NKG2A increases activity of human natural killer cells and clears hepatitis B virus infection in mice","volume":"144","author":"Li","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.scib.2025.01.002_b0205","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.3389\/fimmu.2018.01124","article-title":"Decreased siglec-9 expression on natural killer cell subset associated with persistent HBV replication","volume":"9","author":"Zhao","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.scib.2025.01.002_b0210","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.888248","article-title":"Natural killer cells in SARS-CoV-2 infection: pathophysiology and therapeutic implications","volume":"13","author":"Di Vito","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.scib.2025.01.002_b0215","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1093\/stcltm\/szac057.010","article-title":"Interim results of a phase I study investigating a cord blood-derived natural killer cell therapy for patients hospitalized with COVID-19","volume":"11","author":"Tercero","year":"2022","journal-title":"Stem Cell Transl Med"},{"key":"10.1016\/j.scib.2025.01.002_b0220","doi-asserted-by":"crossref","first-page":"CT201","DOI":"10.1158\/1538-7445.AM2021-CT201","article-title":"Early report of a phase I\/II study of human placental hematopoietic stem cell derived natural killer cells (CYNK-001) for the treatment of adults with COVID-19 (NCT04365101)","volume":"81","author":"Casper","year":"2021","journal-title":"Cancer Res"},{"key":"10.1016\/j.scib.2025.01.002_b0225","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jcyt.2023.10.002","article-title":"Results of phase 2 randomized multi-center study to evaluate the safety and efficacy of infusion of memory T cells as adoptive therapy in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia and\/or lymphopenia (RELEASE NCT04578210)","volume":"26","author":"Ferreras","year":"2024","journal-title":"Cytotherapy"},{"key":"10.1016\/j.scib.2025.01.002_b0230","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/s41423-023-01046-5","article-title":"Expanded clinical-grade NK cells exhibit stronger effects than primary NK cells against HCMV infection","volume":"20","author":"Shang","year":"2023","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.scib.2025.01.002_b0235","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1093\/infdis\/jiad578","article-title":"Safety and virologic impact of haploidentical NK cells plus interleukin 2 or N-803 in HIV infection","volume":"229","author":"Miller","year":"2024","journal-title":"J Infect Dis"},{"key":"10.1016\/j.scib.2025.01.002_b0240","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1002\/eji.201948375","article-title":"Expanded clinical-grade membrane-bound IL-21\/4-1BBL NK cell products exhibit activity against acute myeloid leukemia in vivo","volume":"50","author":"Zhao","year":"2020","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.scib.2025.01.002_b0245","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/bjh.17186","article-title":"Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity","volume":"193","author":"Rafei","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.scib.2025.01.002_b0250","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13046-022-02327-z","article-title":"CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy","volume":"41","author":"Pan","year":"2022","journal-title":"J Exp Clin Canc Res"},{"key":"10.1016\/j.scib.2025.01.002_b0255","article-title":"Target tumor microenvironment by innate T cells","volume":"13","author":"Li","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.scib.2025.01.002_b0260","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1016\/j.bbmt.2016.09.006","article-title":"Early natural killer cell reconstitution predicts overall survival in T cell-replete allogeneic hematopoietic stem cell transplantation","volume":"22","author":"Minculescu","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.scib.2025.01.002_b0265","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.scib.2025.01.002_b0270","article-title":"Advances in CAR-NK cell therapy for hematological malignancies","volume":"15","author":"Yang","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.scib.2025.01.002_b0275","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/s41423-021-00808-3","article-title":"Advances in NK cell production","volume":"19","author":"Fang","year":"2022","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.scib.2025.01.002_b0280","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1182\/blood-2004-07-2974","article-title":"Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer","volume":"105","author":"Miller","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.scib.2025.01.002_b0285","first-page":"1083","article-title":"First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia","volume":"8","author":"Tang","year":"2018","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.scib.2025.01.002_b0290","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"New Engl J Med"},{"key":"10.1016\/j.scib.2025.01.002_b0295","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/s41392-022-01058-z","article-title":"Natural killer cell homing and trafficking in tissues and tumors: from biology to application","volume":"7","author":"Ran","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.scib.2025.01.002_b0300","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1084\/jem.20100282","article-title":"Age-dependent susceptibility to a viral disease due to decreased natural killer cell numbers and trafficking","volume":"207","author":"Fang","year":"2010","journal-title":"J Exp Med"},{"key":"10.1016\/j.scib.2025.01.002_b0305","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nature22395","article-title":"Therapeutic T cell engineering","volume":"545","author":"Sadelain","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.scib.2025.01.002_b0310","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1158\/1535-7163.MCT-19-1109","article-title":"Shaping functional avidity of CAR T cells: affinity, avidity, and antigen density that regulate response","volume":"20","author":"Greenman","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.scib.2025.01.002_b0315","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.bbrc.2020.03.071","article-title":"Impact of scFv structure in chimeric antigen receptor on receptor expression efficiency and antigen recognition properties","volume":"527","author":"Fujiwara","year":"2020","journal-title":"Biochem Bioph Res Commun"},{"key":"10.1016\/j.scib.2025.01.002_b0320","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13045-021-01083-5","article-title":"Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy","volume":"14","author":"Gong","year":"2021","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.scib.2025.01.002_b0325","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s40164-023-00461-8","article-title":"Single VHH-directed BCMA CAR-NK cells for multiple myeloma","volume":"12","author":"Ren","year":"2023","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.scib.2025.01.002_b0330","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.omto.2022.02.015","article-title":"A novel PD-L1-targeted shark V single-domain-based CAR-T cell strategy for treating breast cancer and liver cancer","volume":"24","author":"Li","year":"2022","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/j.scib.2025.01.002_b0335","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1407898","article-title":"Development of chimeric antigen receptors targeting T-cell malignancies using two structurally different anti-CD5 antigen binding domains in NK and CRISPR-edited T cell lines","volume":"7","author":"Raikar","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.scib.2025.01.002_b0340","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41422-024-00936-1","article-title":"CAR-Toner: an AI-driven approach for CAR tonic signaling prediction and optimization","volume":"34","author":"Qiu","year":"2024","journal-title":"Cell Res"},{"key":"10.1016\/j.scib.2025.01.002_b0345","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1158\/2326-6066.CIR-14-0127","article-title":"The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for antitumor activity","volume":"3","author":"Hudecek","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.scib.2025.01.002_b0350","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12896-023-00827-0","article-title":"Tuning spacer length improves the functionality of the nanobody-based VEGFR2 CAR T cell","volume":"24","author":"Taheri","year":"2024","journal-title":"BMC Biotechnol"},{"key":"10.1016\/j.scib.2025.01.002_b0355","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.4049\/jimmunol.1400330","article-title":"DAP12-based activating chimeric antigen receptor for NK cell tumor immunotherapy","volume":"194","author":"T\u00f6pfer","year":"2015","journal-title":"J Immunol"},{"key":"10.1016\/j.scib.2025.01.002_b0360","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.scib.2025.01.002_b0365","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1186\/s13287-021-02462-y","article-title":"CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies","volume":"12","author":"Marofi","year":"2021","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.scib.2025.01.002_b0370","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1182\/blood-2004-12-4797","article-title":"Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells","volume":"106","author":"Imai","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.scib.2025.01.002_b0375","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/s41587-019-0329-2","article-title":"The therapeutic landscape for cells engineered with chimeric antigen receptors","volume":"38","author":"MacKay","year":"2020","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.scib.2025.01.002_b0380","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1158\/2159-8290.CD-24-0096","article-title":"CD28 costimulation augments CAR signaling in NK cells via the LCK\/CD3zeta\/ZAP70 signaling axis","volume":"14","author":"Acharya","year":"2024","journal-title":"Cancer Discov"},{"key":"10.1016\/j.scib.2025.01.002_b0385","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.stem.2018.06.002","article-title":"Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity","volume":"23","author":"Li","year":"2018","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.scib.2025.01.002_b0390","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.2147\/CMAR.S253565","article-title":"DNAM1 and 2B4 costimulatory domains enhance the cytotoxicity of anti-GPC3 chimeric antigen receptor-modified natural killer cells against hepatocellular cancer cells in vitro","volume":"12","author":"Huang","year":"2020","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.scib.2025.01.002_b0395","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1038\/s41423-021-00732-6","article-title":"Chimeric antigen receptor- and natural killer cell receptor-engineered innate killer cells in cancer immunotherapy","volume":"18","author":"Zhang","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.scib.2025.01.002_b0400","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/leu.2017.226","article-title":"Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity","volume":"32","author":"Liu","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.scib.2025.01.002_b0405","doi-asserted-by":"crossref","first-page":"706","DOI":"10.3390\/cancers12030706","article-title":"You have got a fast CAR: chimeric antigen receptor NK Cells in cancer therapy","volume":"12","author":"Pfefferle","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.scib.2025.01.002_b0410","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1007\/s12185-021-03209-4","article-title":"Engineering the next generation of CAR-NK immunotherapies","volume":"114","author":"Biederst\u00e4dt","year":"2021","journal-title":"Int J Hematol"},{"key":"10.1016\/j.scib.2025.01.002_b0415","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1016\/j.cell.2023.07.036","article-title":"TGF-\u03b2 signaling in health and disease","volume":"186","author":"Massagu\u00e9","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.scib.2025.01.002_b0420","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.stem.2024.06.009","article-title":"Disruption of TGF-\u03b2 signaling pathway is required to mediate effective killing of hepatocellular carcinoma by human iPSC-derived NK cells","author":"Thangaraj","year":"2024","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.scib.2025.01.002_b0425","doi-asserted-by":"crossref","first-page":"e1274","DOI":"10.1002\/cti2.1274","article-title":"CAR-NK cells: the next wave of cellular therapy for cancer","volume":"10","author":"Daher","year":"2021","journal-title":"Clin Transl Immunology"},{"key":"10.1016\/j.scib.2025.01.002_b0430","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1182\/blood.2019000621","article-title":"Pluripotent stem cell-derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity","volume":"135","author":"Zhu","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.scib.2025.01.002_b0435","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2122379119","article-title":"Memory-like NK cells armed with a neoepitope-specific CAR exhibit potent activity against NPM1 mutated acute myeloid leukemia","volume":"119","author":"Dong","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.scib.2025.01.002_b0440","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.611163","article-title":"Engineering NK cells for CAR therapy-recent advances in gene transfer methodology","volume":"11","author":"Schmidt","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.scib.2025.01.002_b0445","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1093\/jleuko\/qiad074","article-title":"Nonviral technologies can pave the way for CAR-NK cell therapy","volume":"114","author":"Bexte","year":"2023","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.scib.2025.01.002_b0450","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.omtm.2020.03.017","article-title":"Rosuvastatin enhances VSV-G lentiviral transduction of NK cells via upregulation of the low-density lipoprotein receptor","volume":"17","author":"Gong","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.scib.2025.01.002_b0455","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.3389\/fimmu.2019.02873","article-title":"Efficient and robust NK-cell transduction with Baboon envelope pseudotyped lentivector","volume":"10","author":"Colamartino","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.scib.2025.01.002_b0460","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1016\/j.scib.2023.09.048","article-title":"Classification of five SARS-CoV-2 serotypes based on RBD antigenicities","volume":"68","author":"Hu","year":"2023","journal-title":"Sci Bull"},{"key":"10.1016\/j.scib.2025.01.002_b0465","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41580-021-00418-x","article-title":"Mechanisms of SARS-CoV-2 entry into cells","volume":"23","author":"Jackson","year":"2022","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.scib.2025.01.002_b0470","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adl4013","article-title":"In vitro selection and analysis of SARS-CoV-2 nirmatrelvir resistance mutations contributing to clinical virus resistance surveillance","volume":"10","author":"Zhu","year":"2024","journal-title":"Sci Adv"},{"key":"10.1016\/j.scib.2025.01.002_b0475","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41579-021-00573-0","article-title":"SARS-CoV-2 variants, spike mutations and immune escape","volume":"19","author":"Harvey","year":"2021","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.scib.2025.01.002_b0480","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1016\/j.scib.2024.02.041","article-title":"Development of T cell antigen-based human coronavirus vaccines against nAb-escaping SARS-CoV-2 variants","volume":"69","author":"Zhou","year":"2024","journal-title":"Sci Bull"},{"key":"10.1016\/j.scib.2025.01.002_b0485","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1016\/j.immuni.2021.09.002","article-title":"Early IFN-alpha signatures and persistent dysfunction are distinguishing features of NK cells in severe COVID-19","volume":"54","author":"Kramer","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.scib.2025.01.002_b0490","doi-asserted-by":"crossref","DOI":"10.1080\/22221751.2024.2361019","article-title":"SARS-CoV-2 infection induces adaptive NK cell responses by spike protein-mediated induction of HLA-E expression","volume":"13","author":"Hasan","year":"2024","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.scib.2025.01.002_b0495","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.848886","article-title":"Persistent overactive cytotoxic immune response in a Spanish cohort of individuals with long-COVID: identification of diagnostic biomarkers","volume":"13","author":"Gal\u00e1n","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.scib.2025.01.002_b0500","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1038\/s41467-021-23621-y","article-title":"Clinical and molecular characteristics of COVID-19 patients with persistent SARS-CoV-2 infection","volume":"12","author":"Yang","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.scib.2025.01.002_b0505","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.652223","article-title":"CAR-NK cells effectively target SARS-CoV-2-spike-expressing cell lines in vitro","volume":"12","author":"Ma","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.scib.2025.01.002_b0510","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.763460","article-title":"Glycoprotein targeted CAR-NK cells for the treatment of SARS-CoV-2 infection","volume":"12","author":"Christodoulou","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.scib.2025.01.002_b0515","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.cell.2015.09.056","article-title":"Engineering a therapeutic lectin by uncoupling mitogenicity from antiviral activity","volume":"163","author":"Swanson","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.scib.2025.01.002_b0520","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1038\/s41467-022-30216-8","article-title":"Off-the-shelf CAR natural killer cells secreting IL-15 target spike in treating COVID-19","volume":"13","author":"Lu","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.scib.2025.01.002_b0525","unstructured":"GBD 2021 HIV Collaborators. Global, regional, and national burden of HIV\/AIDS, 1990-2021, and forecasts to 2050, for 204 countries and territories: the Global Burden of Disease Study 2021. Lancet HIV 2024, 11: e807\u2013e22."},{"key":"10.1016\/j.scib.2025.01.002_b0530","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.chom.2020.03.014","article-title":"The biology of the HIV-1 latent reservoir and implications for cure strategies","volume":"27","author":"Cohn","year":"2020","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.scib.2025.01.002_b0535","first-page":"1344","article-title":"HIV Infection - screening, diagnosis, and treatment","volume":"385","author":"De Socio","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.scib.2025.01.002_b0540","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.immuni.2023.01.030","article-title":"HIV rapidly targets a diverse pool of CD4+T cells to establish productive and latent infections","volume":"56","author":"Gantner","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.scib.2025.01.002_b0545","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41577-018-0085-4","article-title":"Functional cure of HIV: the scale of the challenge","volume":"19","author":"Davenport","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.scib.2025.01.002_b0550","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.virol.2020.08.007","article-title":"Natural killer cell counts in primary HIV infection predicts disease progression and immune restoration after treatment","volume":"550","author":"Wang","year":"2020","journal-title":"Virology"},{"key":"10.1016\/j.scib.2025.01.002_b0555","doi-asserted-by":"crossref","first-page":"e01790","DOI":"10.1128\/JVI.01790-18","article-title":"Identification of NK cell subpopulations that differentiate HIV-infected subject cohorts with diverse levels of virus control","volume":"93","author":"Pohlmeyer","year":"2019","journal-title":"J Virol"},{"key":"10.1016\/j.scib.2025.01.002_b0560","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adi3974","article-title":"Antigen-specific memory NK cell responses against HIV and influenza use the NKG2\/HLA-E axis","volume":"8","author":"Jost","year":"2023","journal-title":"Sci Immunol"},{"key":"10.1016\/j.scib.2025.01.002_b0565","article-title":"Negative regulation and protective function of natural killer cells in HIV infection: two sides of a coin","volume":"13","author":"Sun","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.scib.2025.01.002_b0570","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/stem.1611","article-title":"Expression of chimeric receptor CD4\u03b6 by natural killer cells derived from human pluripotent stem cells improves in vitro activity but does not enhance suppression of HIV infection in vivo","volume":"32","author":"Ni","year":"2014","journal-title":"Stem Cells"},{"key":"10.1016\/j.scib.2025.01.002_b0575","doi-asserted-by":"crossref","first-page":"8031","DOI":"10.1073\/pnas.122696599","article-title":"Cell surface expression of the HIV-1 envelope glycoproteins is directed from intracellular CTLA-4-containing regulated secretory granules","volume":"99","author":"Miranda","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.scib.2025.01.002_b0580","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1084\/jem.20161160","article-title":"Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo","volume":"214","author":"Medina-Ramirez","year":"2017","journal-title":"J Exp Med"},{"key":"10.1016\/j.scib.2025.01.002_b0585","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1021\/acschembio.0c00537","article-title":"A universal CAR-NK cell targeting various epitopes of HIV-1 gp160","volume":"15","author":"Lim","year":"2020","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.scib.2025.01.002_b0590","doi-asserted-by":"crossref","DOI":"10.1172\/JCI150211","article-title":"Broadly neutralizing antibody-derived CAR T cells reduce viral reservoir in individuals infected with HIV-1","volume":"131","author":"Liu","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1016\/j.scib.2025.01.002_b0595","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav5685","article-title":"Multispecific anti-HIV duoCAR-T cells display broad in vitro antiviral activity and potent in vivo elimination of HIV-infected cells in a humanized mouse model","volume":"11","author":"Anthony-Gonda","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.scib.2025.01.002_b0600","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.161698","article-title":"In vivo killing of primary HIV-infected cells by peripheral-injected early memory-enriched anti-HIV duoCAR T cells","volume":"7","author":"Anthony-Gonda","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.scib.2025.01.002_b0605","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1038\/s41591-020-1039-5","article-title":"Dual CD4-based CAR T cells with distinct costimulatory domains mitigate HIV pathogenesis in vivo","volume":"26","author":"Maldini","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.scib.2025.01.002_b0610","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41421-024-00658-z","article-title":"Efficacy and safety of novel multifunctional M10 CAR-T cells in HIV-1-infected patients: a phase I, multicenter, single-arm, open-label study","volume":"10","author":"Mao","year":"2024","journal-title":"Cell Discov"},{"key":"10.1016\/j.scib.2025.01.002_b0615","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/s41575-023-00760-9","article-title":"Global burden of hepatitis B virus: current status, missed opportunities and a call for action","volume":"20","author":"Hsu","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.scib.2025.01.002_b0620","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.jhep.2014.04.041","article-title":"Hepatitis B virus PreS\/S gene variants: pathobiology and clinical implications","volume":"61","author":"Pollicino","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.scib.2025.01.002_b0625","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/hep.28280","article-title":"Antiviral therapy for chronic hepatitis B viral infection in adults: a systematic review and meta-analysis","volume":"63","author":"Lok","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.scib.2025.01.002_b0630","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1084109","article-title":"Prospects for NK-based immunotherapy of chronic HBV infection","volume":"13","author":"Jin","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.scib.2025.01.002_b0635","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.29142","article-title":"IL-21 collaborates with anti-TIGIT to restore NK cell function in chronic HBV infection","volume":"95","author":"Tang","year":"2023","journal-title":"J Med Virol"},{"key":"10.1016\/j.scib.2025.01.002_b0640","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1053\/j.gastro.2007.11.002","article-title":"T cells redirected against hepatitis B virus surface proteins eliminate infected hepatocytes","volume":"134","author":"Bohne","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.scib.2025.01.002_b0645","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.jcyt.2018.02.002","article-title":"HBsAg-redirected T cells exhibit antiviral activity in HBV-infected human liver chimeric mice","volume":"20","author":"Kruse","year":"2018","journal-title":"Cytotherapy"},{"key":"10.1016\/j.scib.2025.01.002_b0650","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.virol.2023.06.015","article-title":"PreS1-targeting chimeric antigen receptor T cells diminish HBV infection in liver humanized FRG mice","volume":"586","author":"Guo","year":"2023","journal-title":"Virology"},{"key":"10.1016\/j.scib.2025.01.002_b0655","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.ymthe.2019.02.001","article-title":"Evaluation of a fully human, hepatitis B virus-specific chimeric antigen receptor in an immunocompetent mouse model","volume":"27","author":"Festag","year":"2019","journal-title":"Mol Ther"},{"key":"10.1016\/j.scib.2025.01.002_b0660","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1340619","article-title":"CARs derived from broadly neutralizing, human monoclonal antibodies identified by single B cell sorting target hepatitis B virus-positive cells","volume":"15","author":"Schreiber","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.scib.2025.01.002_b0665","doi-asserted-by":"crossref","first-page":"e2034","DOI":"10.1002\/rmv.2034","article-title":"Estimation of the worldwide seroprevalence of cytomegalovirus: a systematic review and meta-analysis","volume":"29","author":"Zuhair","year":"2019","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.scib.2025.01.002_b0670","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1007\/s00277-020-04201-4","article-title":"Comparison of different cytomegalovirus diseases following haploidentical hematopoietic stem cell transplantation","volume":"99","author":"Meng","year":"2020","journal-title":"Ann Hematol"},{"key":"10.1016\/j.scib.2025.01.002_b0675","doi-asserted-by":"crossref","first-page":"11785","DOI":"10.3389\/ti.2023.11785","article-title":"New treatment options for refractory\/resistant CMV infection","volume":"36","author":"Walti","year":"2023","journal-title":"Transpl Int"},{"key":"10.1016\/j.scib.2025.01.002_b0680","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1093\/infdis\/jiaa462","article-title":"Drug resistance mutations and associated phenotypes detected in clinical trials of maribavir for treatment of cytomegalovirus infection","volume":"226","author":"Chou","year":"2022","journal-title":"J Infect Dis"},{"key":"10.1016\/j.scib.2025.01.002_b0685","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41409-023-01920-w","article-title":"Cytomegalovirus breakthrough and resistance during letermovir prophylaxis","volume":"58","author":"Perchetti","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.scib.2025.01.002_b0690","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1111\/bjh.19451","article-title":"Letermovir prophylaxis reduced cytomegalovirus reactivation and resistance post umbilical cord blood transplantation","volume":"204","author":"Yan","year":"2024","journal-title":"Br J Haematol"},{"key":"10.1016\/j.scib.2025.01.002_b0695","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/ajh.26535","article-title":"Adoptive therapy with cytomegalovirus-specific T cells for cytomegalovirus infection after haploidentical stem cell transplantation and factors affecting efficacy","volume":"97","author":"Pei","year":"2022","journal-title":"Am J Hematol"},{"key":"10.1016\/j.scib.2025.01.002_b0700","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/s41423-021-00829-y","article-title":"Comparable anti-CMV responses of transplant donor and third-party CMV-specific T cells for treatment of CMV infection after allogeneic stem cell transplantation","volume":"19","author":"Pei","year":"2022","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.scib.2025.01.002_b0705","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1128\/JVI.01551-10","article-title":"Identification of binary interactions between human cytomegalovirus virion proteins","volume":"85","author":"Phillips","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.scib.2025.01.002_b0710","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1089\/hum.2019.149","article-title":"Adult and cord blood-derived high-affinity gB-CAR-T cells effectively react against human cytomegalovirus infections","volume":"31","author":"Olbrich","year":"2020","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.scib.2025.01.002_b0715","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1093\/infdis\/jiaa171","article-title":"Chimeric antigen receptors targeting human cytomegalovirus","volume":"222","author":"Ali","year":"2020","journal-title":"J Infect Dis"},{"key":"10.1016\/j.scib.2025.01.002_b0720","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1158\/2326-6066.CIR-15-0098","article-title":"NKG2D receptor and its ligands in host defense","volume":"3","author":"Lanier","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.scib.2025.01.002_b0725","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3390\/microorganisms7060183","article-title":"Epstein-Barr virus and innate Immunity: friends or foes?","volume":"7","author":"Jangra","year":"2019","journal-title":"Microorganisms"},{"key":"10.1016\/j.scib.2025.01.002_b0730","doi-asserted-by":"crossref","first-page":"e130","DOI":"10.1038\/emm.2014.109","article-title":"EBV and human cancer","volume":"47","author":"Ko","year":"2015","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.scib.2025.01.002_b0735","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10875-019-00711-7","article-title":"How I manage natural killer cell deficiency","volume":"40","author":"Orange","year":"2020","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.scib.2025.01.002_b0740","doi-asserted-by":"crossref","first-page":"300","DOI":"10.3390\/v13020300","article-title":"The role of NK cells in EBV infection and EBV-associated NPC","volume":"13","author":"Png","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.scib.2025.01.002_b0745","doi-asserted-by":"crossref","DOI":"10.1172\/JCI163548","article-title":"Patient-tailored adoptive immunotherapy with EBV-specific T cells from related and unrelated donors","volume":"133","author":"Bonifacius","year":"2023","journal-title":"J Clin Invest"},{"key":"10.1016\/j.scib.2025.01.002_b0750","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1182\/blood-2018-07-863654","article-title":"EBV\/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation","volume":"132","author":"McLaughlin","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.scib.2025.01.002_b0755","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1128\/JVI.02183-15","article-title":"The missing link in Epstein-Barr virus immune evasion: the BDLF3 gene induces ubiquitination and downregulation of major histocompatibility complex class I (MHC-I) and MHC-II","volume":"90","author":"Quinn","year":"2016","journal-title":"J Virol"},{"key":"10.1016\/j.scib.2025.01.002_b0760","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.omto.2020.08.005","article-title":"CAR-T cells targeting Epstein-Barr virus gp350 validated in a humanized mouse model of EBV infection and lymphoproliferative disease","volume":"18","author":"Slabik","year":"2020","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/j.scib.2025.01.002_b0765","article-title":"GMP development and preclinical validation of CAR-T cells targeting a lytic EBV antigen for therapy of EBV-associated malignancies","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.scib.2025.01.002_b0770","doi-asserted-by":"crossref","first-page":"9341","DOI":"10.2147\/OTT.S221040","article-title":"CD137 co-stimulation improves the antitumor effect of LMP1-specific chimeric antigen receptor T cells in vitro and in vivo","volume":"12","author":"Tang","year":"2019","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.scib.2025.01.002_b0775","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000736","article-title":"CAR-T cells and TRUCKs that recognize an EBNA-3C-derived epitope presented on HLA-B*35 control Epstein-Barr virus-associated lymphoproliferation","volume":"8","author":"Dragon","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.scib.2025.01.002_b0780","doi-asserted-by":"crossref","DOI":"10.1177\/0963689721996649","article-title":"Successful treatment of pediatric refractory Burkitt lymphoma PTLD after liver transplantation using anti-CD19 chimeric antigen receptor T-cell therapy","volume":"30","author":"Wang","year":"2021","journal-title":"Cell Transplant"},{"key":"10.1016\/j.scib.2025.01.002_b0785","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1086433","article-title":"Non-viral TRAC-knocked-in CD19(KI)CAR-T and gp350(KI)CAR-T cells tested against Burkitt lymphomas with type 1 or 2 EBV infection: in vivo cellular dynamics and potency","volume":"14","author":"Braun","year":"2023","journal-title":"Front Immunol"}],"container-title":["Science Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2095927325000027?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2095927325000027?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T09:42:35Z","timestamp":1778838155000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2095927325000027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":157,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S2095927325000027"],"URL":"https:\/\/doi.org\/10.1016\/j.scib.2025.01.002","relation":{},"ISSN":["2095-9273"],"issn-type":[{"value":"2095-9273","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CAR-NK cell therapy: a potential antiviral platform","name":"articletitle","label":"Article Title"},{"value":"Science Bulletin","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.scib.2025.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. and Science China Press.","name":"copyright","label":"Copyright"}]}}